NY-IFF/EDGE-MOVE-CERT
Regulatory News:
IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition & ingredients, has earned Economic Dividend for Gender Equality (EDGE) Move level certification, globally, making it the first - and currently the only - company to earn this level of recognition.
EDGE is the leading global assessment and business certification for gender equality. Earning certification entails a rigorous third-party review of gender representation, pay equity, the effectiveness of policies and practices and the inclusiveness of an organization’s culture. As part of the assessment, a global survey is also distributed to employees to gauge perception of gender equity in the workplace.
“Knowing IFF is the first company to receive global certification at the EDGE Move level shows that we are aligned with our overarching goals of creating a supportive and empowering environment for all employees,” said IFF Chairman & CEO Andreas Fibig. “Occupations in STEM have historically been a challenging experience for women. With this third-party verification, IFF has created a momentum of accountability and transparency to bolster our efforts for full gender parity.”
Having achieved EDGE Assess in the U.S. last year, IFF went on to achieve EDGE Move globally in 2020 with the certification of 21 countries, making this the largest number of countries ever certified by EDGE at one time. Findings from the assessments led to IFF formalizing policies and procedures supporting gender inclusivity and equality. And results from the 2020 global certification verified that IFF provides equal pay for equivalent work in the 21 countries assessed.
“This certification identified our areas of strength and also highlighted opportunities of growth,” said IFF CHRO and Chief Diversity & Inclusion Officer Susana Suarez. “We are certainly proud of our accomplishments, however our assessment gave us a clear idea of where we can go from here. By focusing on core areas, such as flexible work and recruitment and advancement, among others, we know IFF will be in a better position to support the women and men who call us home today and who will do so in the future.”
As part of IFF’s upcoming 2021 combination with Dupont Nutrition & Biosciences, it is projected that post-merger women will represent 40% of the Executive Committee and 50% of the business unit leads.
“IFF’s milestone achievement of Global EDGE Move certification is a powerful and unambiguous step towards a more inclusive, equitable and prosperous future powered by gender equality,” said EDGE Co-Founder Aniela Unguresan. “Change requires leaders with vision, courage, and resolve. IFF is that kind of leader, leveraging gender equality as a key driver of sustainable business success.”
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005907/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons to acquire AOL following $2.8B debt financing29.10.2025 16:30:00 CET | Press release
Acquisition positions historic brand for its next phase of growth Technology company Bending Spoons today announced that it has entered into a definitive agreement to acquire AOL, the web portal and email provider, from Yahoo. The acquisition is expected to close by the end of the year, subject to customary closing conditions and regulatory approvals. “AOL is an iconic, beloved business that’s in good health, has stood the test of time, and we believe has unexpressed potential,” said Bending Spoons CEO and co-founder, Luca Ferrari. “By our estimation, AOL is one of the top ten most-used email providers in the world, with a highly retained customer base counting around 8 million daily and 30 million monthly active users. We intend to invest significantly to help the product and the business flourish. Bending Spoons has never sold an acquired business—we’re confident we’re the right long-term steward for AOL, and look forward to serving its large, loyal customer base for many years to co
Doha Debates Questions Whether Modern Architecture Contributes to Cultural Decline29.10.2025 16:15:00 CET | Press release
Episode two of flagship debate show asks: Have we lost touch with beauty in the world we have built? This week, Qatar Foundation’s Doha Debates examines how architecture reflects and shapes cultural values on their flagship show, Doha Debates. The second episode of the new season asks: Has modern architecture redefined beauty and tradition, or contributed to its decline? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029822479/en/ Doha Debates brought together a distinguished group of architects, thinkers, and creatives to question whether modern architecture contributes to cultural decline. From left: Sundus Saeed, Ameer Sadi, Sara Akbar, Carl Jambo, Huda Muazzam Iqbal, Tariq Khayyat, Bidisha Sinha, Dareen Abughaida, Carl W. Korsnes, Marwa Al-Sabouni, Leen Nedal Yamin, Wahed Shaik, Lina Ayman Darwish, Mudassar Raza Shakir, and John Carlos Burog. (Photo: AETOSWire) Moderated by Dareen Abughaida, the debate brings students
SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities29.10.2025 15:35:00 CET | Press release
Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise. SK pharmteco and LOTTE BIOLOGICS have announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029483889/en/ Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol
Phenom Named Strategic Leader in 2025 Fosway 9-Grid™ for Talent & People Success for Second Consecutive Year29.10.2025 14:30:00 CET | Press release
Positioning Recognises Phenom Applied AI Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029195746/en/ Phenom has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. Fosway Group identifies Strategi
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®29.10.2025 14:00:00 CET | Press release
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients. Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota® was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease. Ferring
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
